October 24, 2017October 24, 2017

Immune Design’s G100 Receives EMA’s Orphan Drug Designation for Follicular Non-Hodgkin’s Lymphoma

News

The European Medicines Agency (EMA) has granted G100 orphan drug status for the treatment of follicular non-Hodgkin’s lymphoma, Immune Design, the drug’s developer, announced in a press release. The EMA orphan drug designation – ... Read more

August 24, 2017August 24, 2017

Syros Therapy SY-1425 Wins FDA’s Orphan Drug Designation to Treat Acute Myeloid Leukemia

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to SY-1425 to treat acute myeloid leukemia (AML), said the drug’s developer, Syros Pharmaceuticals. The therapy is being tested ... Read more